CARM insider filing: 56,982 shares planned for sale via Morgan Stanley
Rhea-AI Filing Summary
Carisma Therapeutics, Inc. (CARM) filed a Form 144 notifying a proposed sale under Rule 144 of 56,982 common shares held by an insider who acquired the shares via an option grant on 10/22/2018. The filing lists the intended broker as Morgan Stanley Smith Barney LLC and an approximate sale date of 10/07/2025, with an aggregate market value shown as 14182.82. The filer indicates payment for the shares will be treated as compensation and notes no undisclosed material adverse information. The filing also discloses a prior sale by Michael Klichinsky of 484,347 shares on 10/03/2025 for gross proceeds of 124342.96.
Positive
- Sale filed under Rule 144, indicating regulatory compliance with restricted-share resale rules
- Broker identified (Morgan Stanley Smith Barney LLC), supporting an orderly transaction process
Negative
- Large insider sale disclosed recently: 484,347 shares sold on 10/03/2025 for 124,342.96, which may increase share supply
- Low aggregate market value listed for the proposed sale (14182.82) relative to the prior sale proceeds, suggesting pricing/valuation dispersion
Insights
TL;DR: An insider plans a Rule 144 sale of 56,982 shares after exercising options; a recent large sale by a named insider is disclosed.
The notice shows the shares were acquired in an option grant on 10/22/2018 and are being sold through Morgan Stanley Smith Barney LLC with an intended sale date of 10/07/2025. The filing records the nature of payment as compensation, indicating these are likely company-issued stock options rather than open-market purchases.
Disclosure of a prior sale of 484,347 shares on 10/03/2025 for 124,342.96 is material to liquidity and insider selling activity; monitor subsequent Form 4s or additional Rule 144 notices within the next few weeks for further insider disposition.